GE HealthCare closed at $64.81 on September 21, 28% below its 52-week high. On September 22, Needham began coverage with a Buy rating and a $93 target, about 44% above the close, saying market skepticism had made the shares attractively valued.
Pressures cited include stalled sales in China, which accounts for about 13% of revenue, competition from local rivals, tighter hospital budgets and tariffs. Tariffs cut GE HealthCare’s 2025 operating profit by $245 million before some were refunded; budget constraints also led hospitals to delay scanner purchases.
The bullish case points to AI imaging tools and recurring sales of contrast agents and radiopharmaceuticals; the article says the stock trades near 15 times earnings, below peers. GE HealthCare is in talks to acquire Sofie Biosciences for about $1 billion, a deal expected to expand its high-margin imaging portfolio. Risks include potentially lasting market-share losses in China and hospital spending sensitivity. Insider Monkey counted 59 hedge funds holding the stock in Q2 2026, versus 60 the prior quarter.
